Antibiotic Resistance of Helicobacter pylori: Mechanisms and Clinical Implications

Abstract

Helicobacter pylori is a pathogenic bacterium associated with various gastrointestinal diseases, including chronic gastritis, peptic ulcers, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. The increasing rates of H. pylori antibiotic resistance and the emergence of multidrug-resistant strains pose significant challenges to its treatment. This comprehensive review explores the mechanisms underlying the resistance of H. pylori to commonly used antibiotics and the clinical implications of antibiotic resistance. Additionally, potential strategies for overcoming antibiotic resistance are discussed. These approaches aim to improve the treatment outcomes of H. pylori infections while minimizing the development of antibiotic resistance. The continuous evolution of treatment perspectives and ongoing research in this field are crucial for effectively combating this challenging infection.

Helicobacter pylori Infection in Patients with Gastric Cancer: A 2024 Update

“…[46] Antibiotic-and multidrug-resistant forms are becoming more common. [47] Gastritis caused by H. pylori is classified as an infectious condition, and all symptomatic patients need to receive treatment. [48] Methionine-restricted therapies have been shown to inhibit GC.…”

“…Eradication therapy for H. pylori has substantial hurdles. The effective treatment of this difficult infection depends on continued study in this area and the ongoing improvement in therapeutic options [ 47 ].…”